Disclosures for " Evaluating the Therapeutic Potential of Geranylgeraniol (GGOH) in an iPSC-Derived Duchenne Muscular Dystrophy Disease Model"
-
Mrs. Turner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nutricia Danone.
-
MEKALA GUNASEKARAN has nothing to disclose.
-
Dr. Venigalla has nothing to disclose.
-
Hannah Littel has nothing to disclose.
-
Dr. Pacak has received personal compensation in the range of $0-$499 for serving as a Consultant for LifeSciences Consultants. An immediate family member of Dr. Pacak has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurogene. An immediate family member of Dr. Pacak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lupin. An immediate family member of Dr. Pacak has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ITF Therapeutics. An immediate family member of Dr. Pacak has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MLAB Biosciences. An immediate family member of Dr. Pacak has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wiley. An immediate family member of Dr. Pacak has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Academy of Neurology. The institution of Dr. Pacak has received research support from Sarepta Therapeutics. The institution of Dr. Pacak has received research support from Regenerative Medicine MN. The institution of Dr. Pacak has received research support from Greg Marzolf Jr Foundation. The institution of Dr. Pacak has received research support from NIH. The institution of Dr. Pacak has received research support from Viljem Julijan Association for Children with Rare Diseases . The institution of an immediate family member of Dr. Pacak has received research support from Xtraordinary Joy Foundation. The institution of an immediate family member of Dr. Pacak has received research support from Centers for Disease Control and Prevention. The institution of an immediate family member of Dr. Pacak has received research support from National Institutes of Health. The institution of an immediate family member of Dr. Pacak has received research support from Food and Drug Administration. The institution of an immediate family member of Dr. Pacak has received research support from National Initiative for Cockayne Syndrome. The institution of an immediate family member of Dr. Pacak has received research support from Greg Marzolf Jr. Foundation. The institution of an immediate family member of Dr. Pacak has received research support from Sarepta Therapeutics. The institution of an immediate family member of Dr. Pacak has received research support from Duchenne UK - PPMD. The institution of Dr. Pacak has received research support from MN Partnership . Dr. Pacak has received intellectual property interests from a discovery or technology relating to health care. Dr. Pacak has received publishing royalties from a publication relating to health care. An immediate family member of Dr. Pacak has a non-compensated relationship as a Medical Advisory Board with Speak Foundation that is relevant to AAN interests or activities. An immediate family member of Dr. Pacak has a non-compensated relationship as a President (including President Elect and Past President) with Child Neurology Society that is relevant to AAN interests or activities. An immediate family member of Dr. Pacak has a non-compensated relationship as a Board Member with Child Neurology Foundation that is relevant to AAN interests or activities.
-
Dr. Kang has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurogene. Dr. Kang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lupin. Dr. Kang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ITF Therapeutics (Italfarmaco). An immediate family member of Dr. Kang has received personal compensation in the range of $0-$499 for serving as a Consultant for Life Sciences Consultants. Dr. Kang has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MLAB Biosciences. Dr. Kang has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wiley. Dr. Kang has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Academy of Neurology. The institution of Dr. Kang has received research support from Xtraordinary Joy Foundation. The institution of an immediate family member of Dr. Kang has received research support from Sarepta Therapeutics. The institution of Dr. Kang has received research support from Centers for Disease Control and Prevention (CDC). The institution of Dr. Kang has received research support from National Institutes of Health (NIH). The institution of Dr. Kang has received research support from Food and Drug Administration. The institution of Dr. Kang has received research support from National Initiative for Cockayne Syndrome. The institution of Dr. Kang has received research support from Greg Marzolf Jr Foundation. The institution of Dr. Kang has received research support from Sarepta Therapeutics. The institution of Dr. Kang has received research support from Duchenne UK - PPMD. The institution of an immediate family member of Dr. Kang has received research support from Regenerative Medicine MN. The institution of an immediate family member of Dr. Kang has received research support from Greg Marzolf Jr Foundation. The institution of an immediate family member of Dr. Kang has received research support from NIH. The institution of an immediate family member of Dr. Kang has received research support from Viljem Julijan Association for Children with Rare Disease. The institution of Dr. Kang has received research support from Minnesota Partnership. Dr. Kang has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Kang has received intellectual property interests from a discovery or technology relating to health care. Dr. Kang has received publishing royalties from a publication relating to health care. Dr. Kang has a non-compensated relationship as a Medical Advisory Board with Speak Foundation that is relevant to AAN interests or activities. Dr. Kang has a non-compensated relationship as a President (Including President-Elect and Past President) with Child Neurology Society that is relevant to AAN interests or activities. Dr. Kang has a non-compensated relationship as a Board Member with Child Neurology Foundation that is relevant to AAN interests or activities.